InSpark Technologies
InSpark Technologies Announces the Results of the Home Use and Human Factors Study of Vigilant(TM) in People with Diabetes
June 11, 2016 11:00 ET | InSpark Technologies
Vigilant met or exceeded all human factors criteria for safety, comprehension and ease of useEarly evidence of clinical benefit was demonstrated by a 51 percent reduction in the proportion of blood...